- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:59 | Relief Therapeutics Publishes Joint Deck Ahead Of NeuroX Merger; Stock Up | 2 | RTTNews | ||
| 08:17 | Relief Therapeutics mit neuen Zielen wegen Zusammenschluss mit NeuroX | 7 | cash | ||
| 07:03 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination | 649 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination... ► Artikel lesen | |
| RELIEF THERAPEUTICS HOLDING AG ADR Aktie jetzt für 0€ handeln | |||||
| 14.11. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Shareholders Approve Business Combination with NeuroX | 3.031 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
14-Nov-2025 / 18:20 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 29.10. | Relief Therapeutics Shares Surge On Positive Results Of RLF-OD032 Bioequivalent Study | 13 | RTTNews | ||
| 29.10. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 | 1.194 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
29-Oct-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 24.10. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Convenes Extraordinary General Meeting | 1.680 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Convenes Extraordinary General Meeting
24-Oct-2025 / 06:59 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| 08.10. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination | 1.719 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
08-Oct-2025... ► Artikel lesen | |
| 14.08. | Relief Therapeutics erzielt leicht weniger Verlust im ersten Halbjahr | 774 | Moneycab | Genf - Das Biotechunternehmen Relief Therapeutics hat im ersten Halbjahr 2025 leicht weniger Verlust geschrieben. Die liquiden Mittel erhöhten sich gegenüber Ende 2024. Die gesamten Einnahmen verringerten... ► Artikel lesen | |
| 14.08. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Publishes 2025 Half-Year Report | 1.681 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Half Year Results
Relief Therapeutics Publishes 2025 Half-Year Report
14-Aug-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| 11.08. | Relief Therapeutics Holding SA: Relief Therapeutics Advances Publication of 2025 Half-Year Report | 549 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Half Year Results
Relief Therapeutics Advances Publication of 2025 Half-Year Report
11.08.2025 / 07:00 CET/CEST
Relief Therapeutics... ► Artikel lesen | |
| 29.07. | Relief Therapeutics reports proposed business combination with NeuroX | 20 | Seeking Alpha | ||
| 29.07. | Relief Therapeutics Signs Binding Term Sheet For Merger With NeuroX Group | 5 | RTTNews | ||
| 29.07. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze | 1.923 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
29-Jul-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 20.06. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 | 4.509 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 12.06. | Relief Therapeutics Holding SA: Relief Therapeutics Announces Results of Annual General Meeting | 598 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Announces Results of Annual General Meeting
12.06.2025 / 11:00 CET/CEST
Relief Therapeutics Announces... ► Artikel lesen | |
| 22.05. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 | 5.093 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Research Update
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
22-May-2025 / 07:00 CET/CEST
Release of... ► Artikel lesen | |
| 15.05. | Relief Therapeutics Holding SA: Relief Therapeutics Publishes 2025 Annual General Meeting Agenda | 684 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
15.05.2025 / 07:00 CET/CEST
Relief Therapeutics Publishes... ► Artikel lesen | |
| 10.04. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update | 1.619 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Annual Results
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
10-Apr-2025 / 07:00 CET/CEST
Release of an... ► Artikel lesen | |
| 06.03. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion | 6.577 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Merger
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
06-March-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REVIVE THERAPEUTICS | 0,001 | -95,83 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| QIAGEN | 41,790 | +1,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,39 | +0,30 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| ARCELLX | 72,00 | -3,95 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| PRAXIS PRECISION MEDICINES | 186,65 | -2,46 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| OLEMA PHARMACEUTICALS | 25,890 | +3,33 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| JANUX THERAPEUTICS | 33,730 | +7,03 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,535 | +3,79 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,035 | +3,90 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,040 | +12,44 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) | $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,265 | -1,84 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| EVOTEC | 5,510 | +3,96 % | Kaufempfehlung und Großauftrag: Evotec, Nordex, Desert Gold | Sind über 100 % Kursgewinn bei der Nordex-Aktie noch nicht genug? Dies glauben jedenfalls Analysten. Zudem hat der Windturbinenhersteller auch noch einen Großauftrag an Land gezogen. Geht die Rally... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,19 | +3,51 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,960 | +1,09 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| NUVALENT | 108,08 | -1,18 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen |
RELIEF THERAPEUTICS HOLDING AG ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,860 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RELIEF THERAPEUTICS HOLDING AG ADR finden Sie auf Wallstreet Online.